Higher 5-HT1A Receptor Binding Potential During a Major Depressive Episode Predicts Poor Treatment Response: Preliminary Data from a Naturalistic Study
Open Access
- 4 January 2006
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (8) , 1745-1749
- https://doi.org/10.1038/sj.npp.1300992
Abstract
Serotonin 1A (5-HT1A) binding potential (BP) as assessed by positron emission tomography (PET) is higher in major depressive disorder (MDD) in association with the higher expressing GG genotype of the 5-HT1A C-1019G polymorphism. We hypothesize that higher 5-HT1A BP and the GG genotype predict remission failure on antidepressant treatment. We determined 5-HT1A BP by PET and 5-HT1A C-1019G genotype in 43 controls and 22 medication-free MDD subjects. MDD was treated naturalistically and remission was defined as >50% reduction and a score of 10 on the 24 item Hamilton Scale 1 year after initiation of treatment after scanning. Despite equivalent treatment, nonremitters have higher pretreatment cortical BP and the GG genotype is over-represented compared with remitters. Higher 5-HT1A BP, perhaps due to greater gene expression, may predict antidepressant medication nonremission. The findings should be tested in a controlled prospective treatment study.Keywords
This publication has 17 references indexed in Scilit:
- Regional Heterogeneity of 5-HT1A Receptors in Human Cerebellum as Assessed by Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 2005
- Lithium Augmentation Increases the ACTH and Cortisol Response in the Combined DEX/CRH Test in Unipolar Major Depression,Neuropsychopharmacology, 2002
- Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?Journal of Affective Disorders, 2002
- Association of the C(–1019)G 5-HT1A functional promoter polymorphism with antidepressant responseInternational Journal of Neuropsychopharmacology, 1999
- The C(–1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findingsInternational Journal of Neuropsychopharmacology, 1999
- Relapse of Depression in Primary Care: Rate and Clinical PredictorsArchives of Family Medicine, 1998
- Residual symptoms after partial remission: an important outcome in depressionPsychological Medicine, 1995
- The Impact of Medication Resistance and Continuation Pharmacotherapy on Relapse following Response to Electroconvulsive Therapy in Major DepressionJournal of Clinical Psychopharmacology, 1990
- Modifications of the Serotonin System by Antidepressant TreatmentsJournal of Clinical Psychopharmacology, 1987
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960